173 related articles for article (PubMed ID: 23594289)
1. Immunohistochemical analysis of the role and relationship between Notch-1 and Oct-4 expression in urinary bladder carcinoma.
Abdou AG; El-Wahed MM; Kandil MA; Samaka RM; Elkady N
APMIS; 2013 Oct; 121(10):982-96. PubMed ID: 23594289
[TBL] [Abstract][Full Text] [Related]
2. [The importance of stem cells in the initiation and development of cancer].
Pergoł P; Nowak-Stepniowska A; Drela K; Padzik-Graczyk A
Postepy Biochem; 2013; 59(1):45-52. PubMed ID: 23821942
[TBL] [Abstract][Full Text] [Related]
3. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer.
Atlasi Y; Mowla SJ; Ziaee SA; Bahrami AR
Int J Cancer; 2007 Apr; 120(7):1598-602. PubMed ID: 17205510
[TBL] [Abstract][Full Text] [Related]
4. Notch-1 regulates proliferation and differentiation of human bladder cancer cell lines by inhibiting expression of Krüppel-like factor 4.
Ai X; Jia Z; Liu S; Wang J; Zhang X
Oncol Rep; 2014 Oct; 32(4):1459-64. PubMed ID: 25109409
[TBL] [Abstract][Full Text] [Related]
5. Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential.
Darini CY; Pisani DF; Hofman P; Pedeutour F; Sudaka I; Chomienne C; Dani C; Ladoux A
Oncogene; 2012 May; 31(19):2438-49. PubMed ID: 21927026
[TBL] [Abstract][Full Text] [Related]
6. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells.
Chang CC; Shieh GS; Wu P; Lin CC; Shiau AL; Wu CL
Cancer Res; 2008 Aug; 68(15):6281-91. PubMed ID: 18676852
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
8. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
9. Canonical Notch signalling is inactive in urothelial carcinoma.
Greife A; Jankowiak S; Steinbring J; Nikpour P; Niegisch G; Hoffmann MJ; Schulz WA
BMC Cancer; 2014 Aug; 14():628. PubMed ID: 25167871
[TBL] [Abstract][Full Text] [Related]
10. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
[TBL] [Abstract][Full Text] [Related]
11. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma.
van der Horst G; Bos L; van der Pluijm G
Mol Cancer Res; 2012 Aug; 10(8):995-1009. PubMed ID: 22714124
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of OCT4 is associated with low differentiation and tumor recurrence in human hepatocellular carcinoma.
Dong Z; Zeng Q; Luo H; Zou J; Cao C; Liang J; Wu D; Liu L
Pathol Res Pract; 2012 Sep; 208(9):527-33. PubMed ID: 22824146
[TBL] [Abstract][Full Text] [Related]
13. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
14. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
Azoulay S; Terry S; Chimingqi M; Sirab N; Faucon H; Gil Diez de Medina S; Moutereau S; Maillé P; Soyeux P; Abbou C; Salomon L; Vacherot F; de La Taille A; Loric S; Allory Y
J Pathol; 2008 Dec; 216(4):460-70. PubMed ID: 18825689
[TBL] [Abstract][Full Text] [Related]
15. Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence.
Huang P; Chen J; Wang L; Na Y; Kaku H; Ueki H; Sasaki K; Yamaguchi K; Zhang K; Saika T; Nasu Y; Watanabe M; Kumon H
Med Oncol; 2012 Jun; 29(2):829-34. PubMed ID: 21533858
[TBL] [Abstract][Full Text] [Related]
16. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
17. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
18. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices.
Ioachim E; Charchanti A; Stavropoulos N; Athanassiou E; Bafa M; Agnantis NJ
Anticancer Res; 2002; 22(6A):3383-8. PubMed ID: 12530091
[TBL] [Abstract][Full Text] [Related]
19. Modeling notch signaling in normal and neoplastic hematopoiesis: global gene expression profiling in response to activated notch expression.
Ganapati U; Tan HT; Lynch M; Dolezal M; de Vos S; Gasson JC
Stem Cells; 2007 Aug; 25(8):1872-80. PubMed ID: 17464091
[TBL] [Abstract][Full Text] [Related]
20. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
